{"id":63425,"date":"2026-04-17T21:02:44","date_gmt":"2026-04-17T13:02:44","guid":{"rendered":"https:\/\/flcube.com\/?p=63425"},"modified":"2026-04-17T21:02:45","modified_gmt":"2026-04-17T13:02:45","slug":"yifan-pharma-expands-european-footprint-licenses-long-acting-g-csf-efbemalenograstim-alfa-to-italys-molteni-farmaceutici","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=63425","title":{"rendered":"Yifan Pharma Expands European Footprint, Licenses Long-Acting G-CSF Efbemalenograstim Alfa to Italy&#8217;s Molteni Farmaceutici"},"content":{"rendered":"\n<p><strong>Yifan Pharmaceutical Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/002019:SHE\">SHE: 002019<\/a>), a leading Chinese biopharmaceutical company, has announced a new <strong>licensing agreement<\/strong> with <strong>L. Molteni &amp; C. dei F.lli Alitti Societ\u00e0 di Esercizio S.p.A.<\/strong> (Molteni Farmaceutici), a prominent Italian pharmaceutical firm. The deal grants Molteni exclusive rights to <strong>develop and commercialize efbemalenograstim alfa (F-627)<\/strong> in <strong>Italy and Poland<\/strong>, marking Yifan\u2019s entry into its <strong>17th European country\/region<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-deal-amp-asset-profile\">Deal &amp; Asset Profile<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Licenser<\/strong><\/td><td>Yifan Pharmaceutical Co., Ltd. (SHE: 002019)<\/td><\/tr><tr><td><strong>Licensee<\/strong><\/td><td>Molteni Farmaceutici (Italy)<\/td><\/tr><tr><td><strong>Asset<\/strong><\/td><td>Efbemalenograstim alfa (F-627)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Prevention and treatment of chemotherapy-induced neutropenia (CIN) in cancer patients<\/td><\/tr><tr><td><strong>Territory<\/strong><\/td><td>Italy and Poland<\/td><\/tr><tr><td><strong>Technology Platform<\/strong><\/td><td>Di-Kine dual-molecule technology<\/td><\/tr><tr><td><strong>Molecule Type<\/strong><\/td><td>Recombinant human G-CSF (rhG-CSF) dimer, Fc-fusion protein expressed in CHO cells<\/td><\/tr><tr><td><strong>Key Attributes<\/strong><\/td><td>Long-acting, potent biological activity<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-amp-commercial-rationale\">Clinical &amp; Commercial Rationale<\/h2>\n\n\n\n<p>Efbemalenograstim alfa is a next-generation <strong>&#8220;white blood cell booster&#8221;<\/strong> designed to mitigate a critical side effect of chemotherapy. By enabling the <strong>rapid proliferation and recovery of neutrophils<\/strong>, the drug significantly <strong>reduces the risk of life-threatening infections<\/strong> in immunocompromised cancer patients, allowing them to stay on their prescribed treatment regimens.<\/p>\n\n\n\n<p>This partnership leverages Molteni Farmaceutici\u2019s established commercial infrastructure and market expertise in Southern and Central Europe to accelerate patient access to this innovative therapy. For Yifan, the deal is a key component of its capital-efficient global expansion strategy, building on a growing network of regional partners across the continent.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-context\">Strategic Context<\/h2>\n\n\n\n<p>The European market for long-acting G-CSF agents is mature but remains essential for comprehensive oncology care. Yifan\u2019s ability to secure its 17th European partnership underscores the strong clinical profile and commercial viability of efbemalenograstim alfa. The use of its proprietary <strong>Di-Kine platform<\/strong> to create a potent, long-acting dimer positions the asset favorably against existing standard-of-care treatments.<\/p>\n\n\n\n<p><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding the regulatory and commercial success of efbemalenograstim alfa in Italy and Poland. Actual results will be subject to local regulatory approvals, pricing and reimbursement negotiations, and market competition.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Yifan Pharmaceutical Co., Ltd. (SHE: 002019), a leading Chinese biopharmaceutical company, has announced a new&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[1281,563],"class_list":["post-63425","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-she-002019","tag-yifan-pharmaceutical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Yifan Pharma Expands European Footprint, Licenses Long-Acting G-CSF Efbemalenograstim Alfa to Italy&#039;s Molteni Farmaceutici - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Yifan Pharmaceutical Co., Ltd. (SHE: 002019), a leading Chinese biopharmaceutical company, has announced a new licensing agreement with L. Molteni &amp; C. dei F.lli Alitti Societ\u00e0 di Esercizio S.p.A. (Molteni Farmaceutici), a prominent Italian pharmaceutical firm. The deal grants Molteni exclusive rights to develop and commercialize efbemalenograstim alfa (F-627) in Italy and Poland, marking Yifan\u2019s entry into its 17th European country\/region.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=63425\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Yifan Pharma Expands European Footprint, Licenses Long-Acting G-CSF Efbemalenograstim Alfa to Italy&#039;s Molteni Farmaceutici\" \/>\n<meta property=\"og:description\" content=\"Yifan Pharmaceutical Co., Ltd. (SHE: 002019), a leading Chinese biopharmaceutical company, has announced a new licensing agreement with L. Molteni &amp; C. dei F.lli Alitti Societ\u00e0 di Esercizio S.p.A. (Molteni Farmaceutici), a prominent Italian pharmaceutical firm. The deal grants Molteni exclusive rights to develop and commercialize efbemalenograstim alfa (F-627) in Italy and Poland, marking Yifan\u2019s entry into its 17th European country\/region.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=63425\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-17T13:02:44+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-17T13:02:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63425#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63425\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Yifan Pharma Expands European Footprint, Licenses Long-Acting G-CSF Efbemalenograstim Alfa to Italy&#8217;s Molteni Farmaceutici\",\"datePublished\":\"2026-04-17T13:02:44+00:00\",\"dateModified\":\"2026-04-17T13:02:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63425\"},\"wordCount\":341,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"SHE: 002019\",\"Yifan Pharmaceutical\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=63425#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63425\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=63425\",\"name\":\"Yifan Pharma Expands European Footprint, Licenses Long-Acting G-CSF Efbemalenograstim Alfa to Italy's Molteni Farmaceutici - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-04-17T13:02:44+00:00\",\"dateModified\":\"2026-04-17T13:02:45+00:00\",\"description\":\"Yifan Pharmaceutical Co., Ltd. (SHE: 002019), a leading Chinese biopharmaceutical company, has announced a new licensing agreement with L. Molteni & C. dei F.lli Alitti Societ\u00e0 di Esercizio S.p.A. (Molteni Farmaceutici), a prominent Italian pharmaceutical firm. The deal grants Molteni exclusive rights to develop and commercialize efbemalenograstim alfa (F-627) in Italy and Poland, marking Yifan\u2019s entry into its 17th European country\\\/region.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63425#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=63425\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63425#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Yifan Pharma Expands European Footprint, Licenses Long-Acting G-CSF Efbemalenograstim Alfa to Italy&#8217;s Molteni Farmaceutici\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Yifan Pharma Expands European Footprint, Licenses Long-Acting G-CSF Efbemalenograstim Alfa to Italy's Molteni Farmaceutici - Insight, China&#039;s Pharmaceutical Industry","description":"Yifan Pharmaceutical Co., Ltd. (SHE: 002019), a leading Chinese biopharmaceutical company, has announced a new licensing agreement with L. Molteni & C. dei F.lli Alitti Societ\u00e0 di Esercizio S.p.A. (Molteni Farmaceutici), a prominent Italian pharmaceutical firm. The deal grants Molteni exclusive rights to develop and commercialize efbemalenograstim alfa (F-627) in Italy and Poland, marking Yifan\u2019s entry into its 17th European country\/region.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=63425","og_locale":"en_US","og_type":"article","og_title":"Yifan Pharma Expands European Footprint, Licenses Long-Acting G-CSF Efbemalenograstim Alfa to Italy's Molteni Farmaceutici","og_description":"Yifan Pharmaceutical Co., Ltd. (SHE: 002019), a leading Chinese biopharmaceutical company, has announced a new licensing agreement with L. Molteni & C. dei F.lli Alitti Societ\u00e0 di Esercizio S.p.A. (Molteni Farmaceutici), a prominent Italian pharmaceutical firm. The deal grants Molteni exclusive rights to develop and commercialize efbemalenograstim alfa (F-627) in Italy and Poland, marking Yifan\u2019s entry into its 17th European country\/region.","og_url":"https:\/\/flcube.com\/?p=63425","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-17T13:02:44+00:00","article_modified_time":"2026-04-17T13:02:45+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=63425#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=63425"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Yifan Pharma Expands European Footprint, Licenses Long-Acting G-CSF Efbemalenograstim Alfa to Italy&#8217;s Molteni Farmaceutici","datePublished":"2026-04-17T13:02:44+00:00","dateModified":"2026-04-17T13:02:45+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=63425"},"wordCount":341,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["SHE: 002019","Yifan Pharmaceutical"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=63425#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=63425","url":"https:\/\/flcube.com\/?p=63425","name":"Yifan Pharma Expands European Footprint, Licenses Long-Acting G-CSF Efbemalenograstim Alfa to Italy's Molteni Farmaceutici - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-04-17T13:02:44+00:00","dateModified":"2026-04-17T13:02:45+00:00","description":"Yifan Pharmaceutical Co., Ltd. (SHE: 002019), a leading Chinese biopharmaceutical company, has announced a new licensing agreement with L. Molteni & C. dei F.lli Alitti Societ\u00e0 di Esercizio S.p.A. (Molteni Farmaceutici), a prominent Italian pharmaceutical firm. The deal grants Molteni exclusive rights to develop and commercialize efbemalenograstim alfa (F-627) in Italy and Poland, marking Yifan\u2019s entry into its 17th European country\/region.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=63425#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=63425"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=63425#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Yifan Pharma Expands European Footprint, Licenses Long-Acting G-CSF Efbemalenograstim Alfa to Italy&#8217;s Molteni Farmaceutici"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63425","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=63425"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63425\/revisions"}],"predecessor-version":[{"id":63426,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63425\/revisions\/63426"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=63425"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=63425"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=63425"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}